PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31607444-5	2019	In contrast, P53 induction by Nutlin and Hsp90 inhibitor AUY922 enhanced the BBB function.	nutlin	30-36	tumor protein p53	Homo sapiens	13-16	
33216890-2	2020	There is concern, however, that nutlin therapy might stimulate the emergence or expansion of TP53-mutated subclones.	nutlin	32-38	tumor protein p53	Homo sapiens	93-97	
24366007-11	2014	Collectively, these results suggest that nutlin-3 induces HO-1 expression via the activation of both JNK which is dependent on ROS generated by p53 translocated to the mitochondria and p38 MAPK which appears to be stimulated by a ROS-independent mechanism, and this HO-1 induction may inhibit nutlin-3-induced apoptosis, constituting a negative feedback loop of p53-induced apoptosis.	nutlin	41-47	tumor protein p53	Homo sapiens	144-147	
26883108-7	2016	In addition, combined treatment with GSK2830371 and doxorubicin or nutlin-3 potentiated cell death through a strong induction of p53 pathway and activation of caspase 9.	nutlin	67-73	tumor protein p53	Homo sapiens	129-132	
24885082-3	2014	In this study we aimed to investigate the functional role of this p53 acetylation in nutlin-sensitivity, and further to explore if nutlin-induced protein acetylation in general could indicate novel targets for the enhancement of nutlin-based therapy.	nutlin	85-91	tumor protein p53	Homo sapiens	66-69	
29932882-9	2018	After treatment with Nutlin, increased nuclear localization of p53 (4.05%-80.56%) was observed in pterygium cells along with increasing Nutlin dosages (from 0 to 50 muM, p < 0.001).	nutlin	21-27	tumor protein p53	Homo sapiens	63-66	
24366007-11	2014	Collectively, these results suggest that nutlin-3 induces HO-1 expression via the activation of both JNK which is dependent on ROS generated by p53 translocated to the mitochondria and p38 MAPK which appears to be stimulated by a ROS-independent mechanism, and this HO-1 induction may inhibit nutlin-3-induced apoptosis, constituting a negative feedback loop of p53-induced apoptosis.	nutlin	41-47	tumor protein p53	Homo sapiens	362-365	
20871630-8	2011	p21 was found to mediate nutlin-induced p53-dependent downregulation of another antiapoptotic protein, survivin, without significantly affecting the apoptotic outcome.	nutlin	25-31	tumor protein p53	Homo sapiens	40-43	
23856246-5	2013	Furthermore, we identify pharmacogenomic correlations between specific variants in genes such as TP53, BRAF, ERBBs, and ATAD5 and anticancer agents such as nutlin, vemurafenib, erlotinib, and bleomycin showing one of many ways the data could be used to validate and generate novel hypotheses for further investigation.	nutlin	156-162	tumor protein p53	Homo sapiens	97-101	
22578852-11	2012	From these results, we concluded that nutlin-3 has an antitumor effect on feline lymphoma cell lines harboring the wt-p53 gene through accumulation and activation of P53 leading to cell cycle arrest and apoptosis.	nutlin	38-44	tumor protein p53	Homo sapiens	118-121	
22578852-11	2012	From these results, we concluded that nutlin-3 has an antitumor effect on feline lymphoma cell lines harboring the wt-p53 gene through accumulation and activation of P53 leading to cell cycle arrest and apoptosis.	nutlin	38-44	tumor protein p53	Homo sapiens	166-169	
19509161-12	2009	A combination of vincristine or actinomycin D with nutlin-3 enhanced the antitumor activity in RMS cell lines with wild-type p53.	nutlin	51-57	tumor protein p53	Homo sapiens	125-128	
20371712-3	2010	Previous studies have reported that Nutlin promotes growth arrest and/or apoptosis in cancer cells that express wild-type p53.	nutlin	36-42	tumor protein p53	Homo sapiens	122-125	
20371712-9	2010	Taken together, these findings reveal that Nutlin treatment can inhibit the migration and invasion capacity of p53 wild-type cells, adding to the potential therapeutic benefit of Nutlin and other small molecule MDM2 inhibitors.	nutlin	43-49	tumor protein p53	Homo sapiens	111-114	
20424123-10	2010	In contrast, doxorubicin or nutlin-3 treatment-both leading to p53-p21 activation-or CDK2 inhibition had no effect on SKP2 regulation in MYCN-amplified cells.	nutlin	28-34	tumor protein p53	Homo sapiens	63-66	
19190243-4	2009	Of note, Nutlin-3 up-regulated Notch1 expression also in primary TP53(wild-type) B-chronic lymphocytic leukemia (B-CLL) cells and the combined use of Nutlin-3 plus pharmacological gamma-secretase inhibitors of the Notch signaling showed a synergistic cytotoxicity in both TP53(wild-type) leukemic cell lines and primary B-CLL cells.	nutlin	9-15	tumor protein p53	Homo sapiens	65-69	
19411846-10	2009	Surprisingly, blocking the transcriptional arm of p53, either via alpha-Amanitin or the p53-specific transcriptional inhibitor Pifithrin alpha, not only fails to inhibit, but greatly potentiates Nutlin-induced apoptosis.	nutlin	195-201	tumor protein p53	Homo sapiens	50-53	
19411846-10	2009	Surprisingly, blocking the transcriptional arm of p53, either via alpha-Amanitin or the p53-specific transcriptional inhibitor Pifithrin alpha, not only fails to inhibit, but greatly potentiates Nutlin-induced apoptosis.	nutlin	195-201	tumor protein p53	Homo sapiens	88-91	
19190243-4	2009	Of note, Nutlin-3 up-regulated Notch1 expression also in primary TP53(wild-type) B-chronic lymphocytic leukemia (B-CLL) cells and the combined use of Nutlin-3 plus pharmacological gamma-secretase inhibitors of the Notch signaling showed a synergistic cytotoxicity in both TP53(wild-type) leukemic cell lines and primary B-CLL cells.	nutlin	9-15	tumor protein p53	Homo sapiens	272-276